FDA Drug Approvals, Newly Elected Board of Directors, and Stock Price Updates on Healthcare Companies - Research Report on Theravance, Quintiles, Ironwood, Progenics, and Immunomedics PR Newswire NEW YORK, December 25, 2013 NEW YORK, December 25, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Theravance Inc. (NASDAQ: THRX), Quintiles Transnational Holdings Inc. (NYSE: Q), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and Immunomedics Inc. (NASDAQ: IMMU). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Theravance Inc. Research Report On December 18, 2013, Theravance Inc. (Theravance), along with GlaxoSmithKline, announced that the US Food and Drug Administration (FDA) has approved ANORO ELLIPTA as a combination anticholinergic/long-acting beta2-adrenergic agonist (LABA) indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. The Company stated that Anoro Ellipta is the first once-daily product approved in the US that combines two long-acting bronchodilators in a single inhaler for the maintenance treatment of COPD, and is not indicated for the relief of acute bronchospasm or for the treatment of asthma. Commenting on the approval, Rick E. Winningham, CEO of Theravance said, "We are very pleased that Anoro Ellipta has become the first once-daily dual bronchodilator approved in the US for the treatment of COPD. This is a significant milestone for Theravance and GSK and is testament to our ongoing partnership and shared commitment to the development of respiratory medicines." The Full Research Report on Theravance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/fa70_THRX -- Quintiles Transnational Holdings Inc. Research Report On December 17, 2013, Quintiles Transnational Holdings Inc. (Quintiles) announced the election of Mr. Richard Relyea to its Board of Directors. The Company stated that Relyea was designated by equity investor 3i to fill a vacancy on its Board of Directors, and came as the result of Denis Ribon's pending departure from 3i and resulting resignation from the Quintiles board. Pursuant to the Quintiles shareholders agreement, 3i retains the right to designate a replacement to the board. The Company also mentioned that prior to the Quintiles IPO, Relyea served as 3i's observer to the Quintiles board. The Full Research Report on Quintiles Transnational Holdings Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/9f5c_Q -- Ironwood Pharmaceuticals Inc. Research Report On December 20, 2013, Ironwood Pharmaceuticals Inc.'s (Ironwood Pharmaceuticals) stock rose 4.63%, ending the day at $11.76. Over the previous three trading sessions, shares of Ironwood Pharmaceuticals gained 10.11% compared to the Nasdaq Composite which gained 2.01% during the same period. The Full Research Report on Ironwood Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/dbc4_IRWD -- Progenics Pharmaceuticals Inc. Research Report On December 20, 2013, Progenics Pharmaceuticals Inc.'s (Progenics Pharmaceuticals) stock rose 4.87%, ending the day at $5.17. Over the previous three trading sessions, shares of Progenics Pharmaceuticals increased 12.64%, significantly beating the Nasdaq Composite which increased 2.01% during the same period. The Full Research Report on Progenics Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/ce17_PGNX -- Immunomedics Inc. Research Report On December 20, 2013, Immunomedics Inc.'s (Immunomedics) stock rose 3.38%, ending the day at $4.28. Over the previous three trading sessions, shares of Immunomedics increased 4.90% compared to the Nasdaq Composite which increased 2.01% during the same period. The Full Research Report on Immunomedics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/c20d_IMMU ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
FDA Drug Approvals, Newly Elected Board of Directors, and Stock Price Updates on Healthcare Companies - Research Report on
Press spacebar to pause and continue. Press esc to stop.